Clinical Trials List
2024-01-25 - 2029-01-31
Phase III
Recruiting7
ICD-10G30.0
Alzheimer's disease with early onset
ICD-10G30.1
Alzheimer's disease with late onset
ICD-10G30.8
Other Alzheimer's disease
ICD-10G30.9
Alzheimer's disease, unspecified
ICD-9331.0
Alzheimer's disease
A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis
-
Trial Applicant
IQVIA RDS Taiwan Ltd.
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/06/18
Investigators and Locations
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- Chen-Chung Liu 無
- CHIH-MIN LIU 無
- YI-TING LIN 無
- Tzung-Jeng Hwang 無
- 謝明憲 無
- 楊焯翔 無
- 林亦廷 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 張芳慈 無
- Hui-Chun Huang 無
- 林欽揚 無
- Hung-Yu Huang 無
- Yu Ao 無
- Yu-Wan Yang 無
- Ming-Kuei Lu 無
- Kuan-Fei Chen 無
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
Subject has successfully completed ACP-204-006 study
Male or female (age 55 to 95 years old): female must be of non-childbearing potential, male must take appropriate contraceptive method if partner has childbearing potential
Subject has a designated study partner/caregiver
Subjects are able to complete all study visits with a study partner/caregiver
Signed inform consent form with a caregiver or legal representative
Exclusion Criteria
Requires treatment with a medication prohibited by the protocol
Is in hospice and receiving end-of-life palliative care, or has become bedridden
Unstable clinically significant medical condition other than AD
Any medical condition that in the opinion of the investigator may affect safety or ability to complete the study
The Estimated Number of Participants
-
Taiwan
24 participants
-
Global
752 participants
